Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds and uses thereof for the modulation of hemoglobin

a technology of compound and use, applied in the field of compound and use for the modulation of hemoglobin, can solve problems such as blood vessel blockage, and achieve the effect of increasing the oxygen affinity of hemoglobin

Inactive Publication Date: 2016-01-28
GLOBAL BLOOD THERAPEUTICS
View PDF1 Cites 40 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about compounds and methods for treating disorders related to hemoglobin, such as oxygen deficiency and sickle cell anemia. The compounds described herein are allosteric modulators of hemoglobin that can increase the affinity of oxygen to the protein. The invention also includes pharmaceutical compositions and methods for administering these compounds to patients in need. Overall, this patent provides new ways to develop drugs that can help improve tissue and cellular oxygenation.

Problems solved by technology

The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds and uses thereof for the modulation of hemoglobin
  • Compounds and uses thereof for the modulation of hemoglobin
  • Compounds and uses thereof for the modulation of hemoglobin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Compound 15

[0235]

[0236]To a solution of 2-bromobenzene-1,3-diol (5 g, 26.45 mmol) in DCM (50 ml) at 0° C. was added DIPFEA ( 11.54 mL, 66.13 mmol) and MOMCl (4.42 ml, 58.19 mmol). The mixture was stirred at 0° C. for 1.5 h, and then warmed to room temperature. The solution was diluted with DCM, washed with sat. NaHCO3, brine, dried and concentrated to give crude product, which was purified by column (hexanes / EtOAc=4:1) to give desired product 15.58 g(90%).

example 2

Synthesis of Compound 13 from 15

[0237]

[0238]To a solution of 2-bromo-1.3-bis(methoxymethoxy)benzene (15) (19.9 g, 71.8 mmol) in THF (150 mL) at −78° C. was added BuLi (2.5 M, 31.6 mL, 79.0 mmol) dropwise. The solution was stirred at −78° C. for 25 min (resulting white cloudy mixture), then it was warmed to 0° C. and stirred for 25 min. The reaction mixture slowly turns homogenous. To the solution was added DMF at 0° C. After 25 min. HPLC showed reaction completed. The mixture was quenched with sat. NH4Cl (150 mL), diluted with ether (300 mL). The organic layer was separated, aq. layer was further extracted with ether (2×200 mL), and organic layer was combined, washed with brine, dried and concentrated to give crude product, which was triturated to give 14.6 g desired product. The filtrate was then concentrated and purified by column to give additional 0.7 g, total mass is 15.3 g.

example 3

Synthesis of Compound 13 from Resorcinol 11

[0239]

[0240]A three-necked round-bottom flask equipped with mechanical stirrer was charged with 0.22 mol of NaH (50 % suspension in mineral oil) under nitrogen atmosphere. NaH was washed with 2 portions (100 mL) of n-hexane and then with 300 mL of dry diethyl ether; then 80 mL of anhydrous DMF was added. Then 0.09 mol of resorcinol 11, dissolved in 100mL of diethyl ether was added dropwise and the mixture was left under stirring at it for 30min. Then 0.18 mol of MOMCl was slowly added. After 1 h under stirring at it, 250 mL of water was added and the organic layer was extracted with diethyl ether, The extracts were washed with brine, dried (Na2SO4)then concentrated to give the crude product that was purified by silica gel chromatography to give compound 12 (93 % yield).

[0241]A three-necked round-bottom flask was charged with 110 mL of n-hexane, 0.79 mol of BuLi and 9.4 mL of tetramethylethylendiamine (TMEDA) under nitrogen atmosphere, the m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
half lifeaaaaaaaaaa
pKaaaaaaaaaaa
pKaaaaaaaaaaa
Login to View More

Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and / or cellular oxygenation.

Description

FIELD OF THE INVENTION[0001]This invention provides compounds and pharmaceutical compositions suitable for use as allosteric modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and / or cellular oxygenation.STATE OF THE ART[0002]Sickle cell disease is a disorder of the red blood cells, found particularly among those of African and Mediterranean descent. The basis for sickle cell disease is found in sickle hemoglobin (HbS), which contains a point mutation relative to the prevalent peptide sequence of hemoglobin (Hb).[0003]Hemoglobin (Hb) transports oxygen molecules from the lungs to various tissues and organs throughout the body. Hemoglobin binds and releases oxygen through conformational changes. Sickle hemoglobin (HbS) contains a point mutation where glutamic acid is replaced with valine, allowing HbS to become susceptible to polymerization to giv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07F9/6558C07D401/04
CPCC07D401/04C07F9/65583
Inventor HARRIS, JASON R.METCALF, BRIAN W.LI, ZHEGWALTNEY, II, STEPHEN L.
Owner GLOBAL BLOOD THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com